StockData
Retension Pharmaceuticals, Inc. logo

Retension Pharmaceuticals, Inc. (RTSN) income statement

RTSNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 18, 2026
$10.51−2.50 (-19.22%)

Close on Nov 20, 2026Market cap $8.49MP/E –Yield –

Retension Pharmaceuticals, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
–

Financial strength

Current ratio
2.12
Debt to equity
–
Debt to assets
–
Cash to current liabilities
138.0%

Valuation

P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–

See a number that looks wrong?